<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04904900</url>
  </required_header>
  <id_info>
    <org_study_id>HBV_GOPC study</org_study_id>
    <nct_id>NCT04904900</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of a Fast-track Treatment Pathway for Patients With Chronic Hepatitis B Under Primary Care</brief_title>
  <official_title>Prospective Evaluation of a Fast-track Treatment Pathway for Patients With Chronic Hepatitis B Under Primary Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective-prospective longitudinal cohort study, with analyses performed before&#xD;
      and after introduction of the pathway, and comparisons made to unexposed controls. We will&#xD;
      launch a protocol-driven management for CHB patients, and provide the appropriate assessment&#xD;
      tools (transient elastography, HBV DNA assay) to general outpatient clinics (GOPC) in Hong&#xD;
      Kong. Patients who fulfil treatment criteria will be referred to specialist outpatient&#xD;
      clinics (SOPC) in a fast-track manner. We will also evaluate the linkage-to-care rate 3 years&#xD;
      before the launch of this care pathway retrospectively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic viral hepatitis is the seventh leading cause of mortality globally, responsible for&#xD;
      1.45 million deaths in 2013. The consequences of chronic hepatitis B and C infection -&#xD;
      cirrhosis and liver cancer - account for 94% of deaths associated with hepatitis.1 Liver&#xD;
      cancer is the second most common cause of cancer death in the Asia-Pacific region.&#xD;
      Approximately 78% of liver cancer cases are a result of chronic viral hepatitis.1,2 In Hong&#xD;
      Kong, the positive rate of hepatitis B surface antigen (HBsAg) remains high among adults of&#xD;
      productive ages of 31-40 and 41-50 years (5.2% and 7.2% respectively) in 2015.3 World Health&#xD;
      Organization (WHO) published the first global health sector strategy on viral hepatitis in&#xD;
      June 2016, a strategy that contributes to the proposed targets for the reduction of chronic&#xD;
      viral hepatitis incidence and mortality of 90% and 65% respectively by 2030.4 The Chief&#xD;
      Executive's 2017 Policy Address in Hong Kong asked to set up the Steering Committee to&#xD;
      formulate strategies to effectively prevent and control viral hepatitis.5 The Steering&#xD;
      Committee is currently reviewing local and international trends and developments in the&#xD;
      prevention and control of viral hepatitis; advising the Government on policies and&#xD;
      cost-effective targeted strategies for prevention and control of viral hepatitis; and&#xD;
      conducting and coordinating the surveillance and evaluation of viral hepatitis control and&#xD;
      recommending appropriate response.5 One of the key gaps in CHB management is the suboptimal&#xD;
      treatment in patients who fulfil treatment criteria but not started on antiviral treatment&#xD;
      because of linkage-to-care issue, namely very long waiting time (up to 2.5 years) from&#xD;
      primary care setting like general outpatient clinics (GOPC). There are limited resources for&#xD;
      specialized assessments (e.g. HBV DNA assays, transient elastography for liver fibrosis&#xD;
      assessment).&#xD;
&#xD;
      Therefore a novel fast-track treatment pathway for patients with chronic hepatitis B under&#xD;
      primary care would fill this gap and provide pivotal data to the Government and the Steering&#xD;
      Committee to guide the strategies for achieving the goals set by WHO.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Linkage-to-care</measure>
    <time_frame>3 years</time_frame>
    <description>referral rate of patients from GOPC and SOPC who fulfil treatment criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unnecessary referral</measure>
    <time_frame>3 years</time_frame>
    <description>referral rate of patients from GOPC and SOPC who do not fulfil treatment criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GOPC care management rate</measure>
    <time_frame>3 years</time_frame>
    <description>transient elastography uptake rate, fibrosis staging, clinical events, default rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOPC care management rate</measure>
    <time_frame>3 years</time_frame>
    <description>antiviral uptake care, fibrosis staging, clinical events, default rate</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3300</enrollment>
  <condition>Chronic Hep B</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample for&#xD;
&#xD;
        -  Liver function test (including albumin, bilirubin, ALT)&#xD;
&#xD;
        -  Alpha-fetoprotein&#xD;
&#xD;
        -  Hepatitis B surface antigen (HBsAg), Hepatitis B e antigen (HBeAg) and antibody to&#xD;
           Hepatitis B e antigen (anti-HBe)&#xD;
&#xD;
        -  HBV DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        300 prospectively from FM/GOPC 3000 retrospectively from CDARS.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with positive hepatitis B surface antigen (HBsAg) for 6 months&#xD;
&#xD;
          -  Under the care of GOPC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18&#xD;
&#xD;
          -  Refusal to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace LH Wong, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angel Chim, MSc</last_name>
    <phone>+852 3505 4205</phone>
    <email>angelchim@cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Chim</last_name>
      <email>angelchim@cuhk.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <link>
    <url>http://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b</url>
    <description>Hepatitis B</description>
  </link>
  <link>
    <url>http://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c</url>
    <description>Hepatitis C</description>
  </link>
  <link>
    <url>https://www.chp.gov.hk/files/pdf/viral_hepatitis_report_2016_final.pdf</url>
    <description>Surveillance of Viral Hepatitis in Hong Kong - 2016 Update Report</description>
  </link>
  <link>
    <url>http://www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/</url>
    <description>Combating hepatitis B and C to reach elimination by 2030</description>
  </link>
  <link>
    <url>https://www.policyaddress.gov.hk/2017/eng/pdf/Agenda_Ch6.pdf</url>
    <description>Building a Caring, Inclusive Society, Improving People's Livelihood</description>
  </link>
  <reference>
    <citation>Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016 Jan;10(1):1-98. doi: 10.1007/s12072-015-9675-4. Epub 2015 Nov 13.</citation>
    <PMID>26563120</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Grace Lai Hung Wong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

